FDA Snubs DVAX, Keep An Eye On OCUL, It's All Green For BLUE

bluebird bio Inc. (BLUE) is all set to present interim data from its phase I study of bb2121 in patients with relapsed/refractory multiple myeloma on December 1, 2016 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium in Munich, Germany.

from RTT - Biotech http://ift.tt/2gadRVO
via IFTTT